FDA
-
-
-
-
-
-
-
Cybin to Transfer U.S. Stock Exchange Listing to Nasdaq
-
-
-
-
-
-
-
Cybin Announces Closing of $175 Million Registered Direct Offering
-
-
-
-
-
-
-
Cybin Completes Enrollment in Phase 2 Study Evaluating CYB004 for the Treatment of Generalized Anxiety Disorder
-
-
-
-
-
-
-
Cybin Reports Important Progress on Key Milestones and First Quarter Fiscal Year 2026 Financial Results
-
-
-
-
-
-
-
Cybin Reports Fiscal Year 2025 Financial Results and Recent Business Highlights
-
-
-
-
-
-
-
Cybin Inc (CYBN) Applauds FDA Commissioner Dr. Martin Makary’s Call to Accelerate and Prioritize Research on Psychedelic Therapeutics
-
-
-
-
-
-
-
Cybin Inc (CYBN) Announces Additional Strategic Clinical Site Partnerships to Support PARADIGM
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

